Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDRi-ADC
- Development stage
- Preclinical
- Lead developer
- Artios Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Artios Pharma is developing a first-in-class DNA damage response inhibitor-antibody drug conjugate (DDRi-ADC) program. This preclinical asset combines the specificity of antibody-drug conjugate technology with the potency of DNA damage response (DDR) inhibitors to target and eliminate cancer cells in hard-to-treat solid tumors. By exploiting DDR pathways, the program aims to precisely target survival mechanisms in cancer cells. Artios expects to nominate a lead candidate for this program in the first quarter of 2026.
- Other names
- DNA damage response inhibitor antibody-drug conjugate
Beyond the preview
Go deeper on DDRi-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDRi-ADC.